MedTrace Logo

DP13 - A Phase II Study in Patients With Primary Aldosteronism

NCT04007406 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-11-22

Study results available
· View outcomes & findings →

Summary

The purpose of the present phase II study is to determine whether DP13 displays the clinical safety and efficacy profile to support further development in patients with primary aldosteronism.

Conditions

  • Primary Aldosteronism

Interventions

DRUG

dexfadrostat phosphate

DP13 systemic administration

Sponsors & Collaborators

  • Damian Pharma AG

    lead INDUSTRY

Principal Investigators

  • Paolo Mulatero, Prof · University of Torino, Torino, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-21
Primary Completion
2022-05-02
Completion
2022-05-02

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04007406 on ClinicalTrials.gov